Hangzhou Tigermed Consulting Co., Ltd (300347.SZ)
Helps pharmaceutical and medical device companies run clinical trials and develop new drugs
50.78+0.06%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-24.2%
The outlook
Tigermed trades near the lower end of its 52-week range with analyst consensus solidly on the buy side, and the average price target sits roughly 25% above the current level. The stock shows mixed momentum against its moving averages, and a high trailing P/E of 55.8 reflects elevated valuations typical of growth expectations in the sector.
What’s behind the score
Analyst consensusBuy — 1.8 avg of 14 analysts
Price trendMixed vs its moving averages
52-week range42% of the way from its 52-week low to high
Price targetAvg target +25% vs current price
Analyst price target
~12-month · 14 analysts63.42average target+24.9% vs now
Now 50.78
Low 41.00High 79.25
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$43.72B
52-wk high
71.90
52-wk low
35.57
50-day avg
43.96
200-day avg
53.02
Trailing P/E
55.8